Back to News
Market Impact: 0.3
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Source: PR Newswire
Healthcare & BiotechPrivate Markets & VentureProduct Launches
North Immunology announced an oversubscribed $180 million financing to advance NOR-101, a half-life-extended anti-IL-13 x IL-18 bispecific antibody for atopic dermatitis. The program is designed to target both type 2 and non-type 2 inflammation, positioning it as a potential best-in-disease treatment candidate. The sizable capital raise strengthens the company’s ability to fund clinical development in a competitive dermatology biologics market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- Waymo to bring autonomous ride-hailing to Singapore in 2028
- Waymo says Singapore will be its next international robotaxi city
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can Hedge Funds Use ChatGPT? A Control Framework
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash